ABT - Abbott Laboratories

NYSE - NYSE Delayed Price. Currency in USD
58.65
+0.34 (+0.58%)
At close: 4:01PM EDT
Stock chart is not supported by your current browser
Previous Close58.31
Open58.04
Bid58.11 x 100
Ask59.27 x 100
Day's Range57.70 - 58.67
52 Week Range42.88 - 64.60
Volume5,909,974
Avg. Volume7,013,275
Market Cap102.422B
Beta1.67
PE Ratio (TTM)218.03
EPS (TTM)0.27
Earnings DateJul 18, 2018 - Jul 23, 2018
Forward Dividend & Yield1.12 (1.90%)
Ex-Dividend DateN/A
1y Target Est68.56
Trade prices are not sourced from all markets
  • Abbott Laboratories Registered Organic Growth of 7% in 1Q18
    Market Realist17 hours ago

    Abbott Laboratories Registered Organic Growth of 7% in 1Q18

    Abbott Laboratories (ABT) is a developer and manufacturer of a broad and diversified line of healthcare products. Its business segments include pharmaceutical products, diagnostic products, nutritional products, and cardiovascular and neuromodulation products.

  • Will BSX’s 1Q18 Results Support Its Upward Trend?
    Market Realist2 days ago

    Will BSX’s 1Q18 Results Support Its Upward Trend?

    Over the last month, BSX stock has registered a rise of ~4.2%. The company came out on top in patent infringement litigation against Edwards Lifesciences (EW), for which a hearing is scheduled in May at the German Court of Appeal. On April 16, Boston Scientific announced its acquisition of Nvision Medical Corporation for a cash payment of $150 million and an additional milestone-based payment over the next four years amounting to $125 million.

  • Boston Scientific’s 1Q18 Revenues: What to Expect
    Market Realist3 days ago

    Boston Scientific’s 1Q18 Revenues: What to Expect

    On April 25, Boston Scientific (BSX) plans to announce its 1Q18 earnings results—the quarter that ended on March 31. According to Wall Street analysts’ estimates, the company’s 1Q18 revenues are expected to come in at $2.34 billion, representing YoY (year-over-year) growth of ~8.4%.

  • Johnson & Johnson’s Revenues Continued to Rise in 1Q18
    Market Realist3 days ago

    Johnson & Johnson’s Revenues Continued to Rise in 1Q18

    Johnson & Johnson (JNJ) reported 12.6% growth in its revenues to $20.0 billion during 1Q18 as compared to revenues of $17.8 billion during 1Q17. The company surpassed Wall Street analyst estimates for EPS (earnings per share) and revenues and reported EPS of $2.06 on revenues of $20.0 billion during 1Q18 against estimates for EPS of $2.00 on revenues of $19.4 billion during 1Q17.

  • Sanquin Selects Abbott's "Alinity™ s" Solution for Blood and Plasma Screening
    PR Newswire3 days ago

    Sanquin Selects Abbott's "Alinity™ s" Solution for Blood and Plasma Screening

    AMSTERDAM, April 23, 2018 /PRNewswire/ -- Sanquin and Abbott (ABT) announced today that they signed a multiple-year contract for the supply of primary serological equipment and consumables, including Abbott's Alinity™ s system, for blood and plasma screening.i This agreement extends Abbott and Sanquin's long-standing relationship of more than 10 years.

  • The Zacks Analyst Blog Highlights: Goldman, Abbott, Altria, PayPal and Progressive
    Zacks3 days ago

    The Zacks Analyst Blog Highlights: Goldman, Abbott, Altria, PayPal and Progressive

    The Zacks Analyst Blog Highlights: Goldman, Abbott, Altria, PayPal and Progressive

  • Financial Times3 days ago

    [$$] Amber Rudd promises easier route to citizenship for Windrush migrants

    Amber Rudd on Monday launched a concerted government effort to silence the furore over the treatment of the “Windrush generation” of migrants from the Caribbean by launching a compensation scheme and a ...

  • Financial Times3 days ago

    [$$] Rudd announces measures to help Windrush generation

    UK home secretary Amber Rudd on Monday made the most concerted effort so far to draw a line under the scandal over the treatment of the Windrush generation of Caribbean immigrants, announcing a package ...

  • Top Analyst Reports for Goldman Sachs, Abbott & Altria
    Zacks6 days ago

    Top Analyst Reports for Goldman Sachs, Abbott & Altria

    Top Analyst Reports for Goldman Sachs, Abbott & Altria

  • Abbott Extends Title Sponsorship of Abbott World Marathon Majors through 2023
    PR Newswire6 days ago

    Abbott Extends Title Sponsorship of Abbott World Marathon Majors through 2023

    LONDON, April 20, 2018 /PRNewswire/ -- Abbott (ABT) and the World Marathon Majors today announced the renewal of Abbott's title sponsorship. Abbott became the first title sponsor of the series in 2015. "At Abbott, we create life-changing technologies that help people live fully and accomplish their personal goals – like running a marathon," said Elaine Leavenworth, senior vice president, chief marketing and external affairs officer, Abbott.

  • Aortic Stenosis, And The Race To Catch Edwards Lifesciences' Heart Valves
    Investor's Business Daily7 days ago

    Aortic Stenosis, And The Race To Catch Edwards Lifesciences' Heart Valves

    Edwards Lifesciences, Medtronic, Boston Scientific and Abbott Laboratories are duking it out for a share of the fast-growing heart-valve replacement market.

  • Abbott Shares Topple After Pharma Unit Struggles In First Quarter
    Investor's Business Daily8 days ago

    Abbott Shares Topple After Pharma Unit Struggles In First Quarter

    Shares of Abbott Laboratories dipped early Wednesday — despite its broad first-quarter beat — on pharmaceutical sales that lagged Wall Street's expectations by nearly 4%.

  • Abbott Laboratories (ABT) Q1 2018 Earnings Conference Call Transcript
    Motley Fool8 days ago

    Abbott Laboratories (ABT) Q1 2018 Earnings Conference Call Transcript

    ABT earnings call for the period ending March 31, 2018.

  • TheStreet.com8 days ago

    Dow Declines Slightly as S&P 500, Nasdaq Post Modest Gains

    rose just 0.06% after posting a 38% increase in first-quarter profit. S&P 500 companies are expected to post an 18.6% increase in first-quarter profit, the biggest rise in seven years, according to Thomson Reuters.

  • TheStreet.com8 days ago

    3 Hot Reads From TheStreet's Top Premium Columnists

    Jim Cramer and our other experts look at banks, three sections to trade, and REITs.

  • Is Abbott Laboratories’s (NYSE:ABT) Balance Sheet Strong Enough To Weather A Storm?
    Simply Wall St.8 days ago

    Is Abbott Laboratories’s (NYSE:ABT) Balance Sheet Strong Enough To Weather A Storm?

    The size of Abbott Laboratories (NYSE:ABT), a US$104.43B large-cap, often attracts investors seeking a reliable investment in the stock market. Doing business globally, large caps tend to have diversified revenueRead More...

  • Abbott sticks to earlier forecasts, disappoints investors
    Reuters8 days ago

    Abbott sticks to earlier forecasts, disappoints investors

    Some analysts also said a 6.9 percent rise in organic sales, which excludes the impact of foreign currency and certain divestitures and acquisitions, was just shy of a roughly 7 percent expected by investors. Thomson Reuters I/B/E/S had no consensus estimate for the organic sales.

  • Abbott Laboratories Stock Slips Despite Earnings Beat
    InvestorPlace8 days ago

    Abbott Laboratories Stock Slips Despite Earnings Beat

    This is an increase over its earnings per share of 48 cents from the same time last year. It also beat out Wall Street’s earnings per share estimate of 58 cents for the period. Net income reported by Abbott Laboratories in the first quarter of 2018 came in at $418 million.

  • Abbott sticks to earlier forecasts, disappoints investors
    Reuters8 days ago

    Abbott sticks to earlier forecasts, disappoints investors

    Some analysts also said a 6.9 percent rise in organic sales, which excludes the impact of foreign currency and certain divestitures and acquisitions, was just shy of a roughly 7 percent expected by investors. Thomson Reuters I/B/E/S had no consensus estimate for the organic sales.

  • TheStreet.com8 days ago

    Abbott CEO: New Glucose Device's U.S. Launch 'Has Gone Exceptionally Well'

    continuous glucose monitoring system FreeStyle Libre is off to a strong start. The debut of Libre, which was approved for sale by the U.S. Food and Drug Administration last September, "has gone exceptionally well," said Abbott chairman and CEO Miles White on an earnings call on Wednesday, April 18. FreeStyle Libre, which was initially launched in Europe in 2014, already has a little over 50,000 users in the U.S., according to White.

  • Abbott (ABT) Q1 Earnings & Revenues Top, '18 View Retained
    Zacks8 days ago

    Abbott (ABT) Q1 Earnings & Revenues Top, '18 View Retained

    Abbott (ABT) continues to gain from a strong and consistent EPD as well as a robust Medical Devices performance.

  • MS, USB, ABT & TXT Leads Q1 Earnings
    Zacks8 days ago

    MS, USB, ABT & TXT Leads Q1 Earnings

    MS, USB, ABT & TXT Leads Q1 Earnings

  • Abbott (ABT) Beats on Earnings and Revenues in Q1
    Zacks8 days ago

    Abbott (ABT) Beats on Earnings and Revenues in Q1

    Abbott (ABT) gains ground on new product launches and delivers strong Q1 results.